Radiotherapiegroep

What Radiotherapiegroep does

Radiotherapiegroep is a Dutch specialized radiotherapy provider (Stichting/foundation) formed on 1 January 2015 from the merger of ARTI (Arnhem, est. 1967) and RISO (Deventer, est. 1955). It operates four treatment locations in the East Netherlands (Arnhem, Deventer, Ede, Apeldoorn) and treats approximately 5,000 cancer patients per year across the full spectrum of radiotherapy modalities: external-beam radiotherapy using cone-beam CT-guided linear accelerators, the Elekta Unity 1.5T MR-Linac (including Comprehensive Motion Management for moving upper-abdomen tumors), stereotactic radiotherapy, and brachytherapy (bladder, vaginal, and prostate – including permanent I-125 implants and HDR). Treatment planning is delivered through RayStation (RaySearch Laboratories), and the organization maintains an in-service training program for radiotherapeutisch laboranten accredited by the College Zorgopleidingen (CZO).

Revenue is generated through Dutch basic health-insurance reimbursement for radiotherapy treatments, billed via Diagnose Behandel Combinaties (DBCs); Radiotherapiegroep contracts with all Dutch health insurers and patients do not pay the organization directly. Go-to-market is referral-driven: patients are routed via Zorgplatform-verwijsorders (preferred), multidisciplinary team meetings, or direct contact with referring specialists in regional hospitals (Rijnstate, Deventer Ziekenhuis, Gelre, Gelderse Vallei, Slingeland, St Jansdal, Saxenburgh), organized into the ARTZ and Veluwe IJssel oncology networks. Supporting infrastructure includes the Mijn Radiotherapiegroep patient portal (DigiD-authenticated), Twiin Afsprakenstelsel integration, the PEM patient-experience monitor (9.1/10 score, 64.6% response rate), and sustainability assets (1,996 solar panels, heat pumps) across sites.

Strategic positioning centers on being one of only five independent radiotherapy institutes in the Netherlands (via the OZRC consortium), operating one of the few Elekta Unity MR-Linacs in the country and pursuing AI-enabled planning and outcome-prediction capability through the €1.5M ZonMw-funded OPERAI consortium (2025–2028) with Maastro and Catharina Ziekenhuis, alongside clinical research participation in protocols such as STARTREC-3 (organ-preserving rectal treatment) and STARTREC-related and other national/international oncology studies.

Name

Radiotherapiegroep

Legal name

Stichting Radiotherapiegroep

Website

https://radiotherapiegroep.nl

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Radiotherapiegroep is a Dutch specialized radiotherapy foundation operating four treatment locations (Arnhem, Deventer, Ede, Apeldoorn) that delivers CBCT- and MR-Linac-guided radiotherapy, brachytherapy and stereotactic treatments to approximately 5,000 cancer patients annually, reimbursed via Dutch basic health insurance and referred through regional oncology networks.

Ownership category

akta.pro rank

Product category

Radiation Oncology Services

NAICS

Diagnostic Imaging Centers (621512), Offices of Other Health Practitioners (6213)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Radiation Oncology (HLAKAFAC)

akta.pro secondary industries

Advanced Imaging & Specialty Radiology Centers (PET/CT, Nuclear Medicine, Interventional Radiology) (HLAFAKAB), Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD)

Keywords

• Radiotherapy treatment
• Oncology services
• Cancer care
• Radiation therapy
• Image-guided radiotherapy

Headquarters

HQ city

Arnhem

HQ country

Netherlands

HQ region

Europe

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Radiotherapy Treatment Services: Radiotherapiegroep is a healthcare provider whose radiotherapy treatments are reimbursed under the Dutch basic health insurance (basisverzekering). The organization has contracts with all Dutch health insurers. Billing is done through DBC (Diagnose Behandel Combinaties). Patients are responsible for the statutory deductible (€385 in 2026). The organization does not bill patients directly — bills go straight to the insurer.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Core offering

Radiotherapiegroep operates specialized radiotherapy treatment centers delivering external beam radiotherapy (CBCT-guided linear accelerators), MRI-guided adaptive radiotherapy (Elekta Unity MR-Linac), stereotactic radiotherapy, and brachytherapy (internal radiation) to cancer patients across four locations in the Netherlands. The organization treats approximately 5,000 patients annually and offers more than 95% of all radiotherapy treatment modalities, with referrals received from regional hospital networks and multidisciplinary oncology teams.

Product overview

Radiotherapiegroep is a specialized radiotherapy treatment center offering a comprehensive range of cancer radiation treatments across four locations (Arnhem, Deventer, Ede, and Apeldoorn). The core offerings include CT-guided external radiotherapy using cone beam CT linear accelerators for precise positioning, MR-Linac radiotherapy combining 1.5T MRI with linear accelerator for real-time tumor tracking and adaptive treatment, stereotactic radiotherapy for high-precision localized treatments, and brachytherapy for internal radiation delivery. Supporting services include the Mijn Radiotherapiegroep patient portal, RayStation treatment planning software, disease-specific patient information brochures, the prostate cancer treatment dashboard developed with Rijnstate, and participation in clinical trials. The center treats approximately 5,000 patients annually with common treatments for prostate, breast, head/neck, lung, and rectal cancers. Key innovations include Comprehensive Motion Management on the MR-Linac and the OPERAI AI project for treatment optimization.

Differentiator

Problem solved

Functional benefit

Products and services

• CBCT-Guided External Beam Radiotherapy External beam radiotherapy delivered via linear accelerators equipped with cone beam CT (CBCT) imaging for precise patient positioning before each session. Images are compared with planning CT scans and any position deviations are automatically corrected. Used for a wide range of cancer types.
• MR-Linac Adaptive Radiotherapy MRI-guided radiotherapy using the Elekta Unity MR-Linac system, which integrates a 1.5 Tesla MRI scanner with a linear accelerator. Enables real-time tumor visualization, daily adaptive treatment planning based on current patient anatomy, and Comprehensive Motion Management (CMM) that automatically pauses treatment when tumor motion exceeds preset margins.
• Stereotactic Radiotherapy High-precision radiation treatment for localized tumors using specialized equipment with an advanced treatment table capable of multi-directional corrections including rotations. Used for treating small, well-defined tumors with high accuracy.
• Brachytherapy (Internal Radiotherapy) Internal radiotherapy where a radiation source is placed in or near the tumor. Available for bladder and vaginal tumors at the Arnhem location, and for prostate cancer (both permanent I-125 implants and temporary HDR treatments) at the Deventer location.
• Mijn Radiotherapiegroep (Patient Portal) Secure online patient portal providing an overview of treatment information, appointment viewing, e-consult functionality, and access to treatment-related documents. Authenticated via DigiD and supported by Helpdesk Digitale Zorg.
• Disease-Specific Treatment Information Brochures Comprehensive patient education brochures covering various cancer types and their radiotherapy treatment pathways, including anal, cervical, bladder, breast, prostate, lung, and esophageal cancer.
• In-Service Training Program for Radiotherapy Technologists 34-month in-service training program for radiotherapy technicians (MBB'ers), combining theoretical education at Erasmus MC Academie in Rotterdam with practical training at Radiotherapiegroep. CZO-accredited for a maximum 5-year period following May 2026 renewal.

Quantifiable outcome

• Average patient satisfaction score of 9.1 out of 10 in the PatiëntErvaringsMonitor (PEM) 2025
• +5 more outcomes

Named customers7 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration12 records

AI capability9 records

Feature7 records

Partnerships

18 partnerships are on record, tiered minor and core.

• Stichting Helpdesk Digitale ZorgminorImplementation/ SI/ Consulting Partner · 10 March 2026Supports Radiotherapiegroep's Mijn Radiotherapiegroep patient portal users with non-medical questions about digital healthcare tools. Helpdesk available Mon-Fri 08:00-18:00 via phone (085-1304-575) and email.
• MaastrocoreStrategic or Co-development Partner · 1 October 2025Joint OPERAI project (Optimale, Passende en Efficiënte Radiotherapie met AI) — a €1.5M ZonMw-funded three-year AI project starting October 2025. Maastro is the coordinator. Project focuses on AI-driven treatment outcome prediction and radiotherapy process automation for five common cancers.
• Catharina ZiekenhuiscoreStrategic or Co-development Partner · 1 October 2025Partner in the OPERAI project alongside Maastro and Radiotherapiegroep, contributing AI expertise and clinical experience with a broad patient population across the Netherlands.
• RaySearch LaboratoriescoreTechnology or Integration · 1 January 2024Technology partner providing RayStation treatment planning software. Radiotherapiegroep collaborates intensively with RaySearch on further development and optimization of treatment planning, including online adaptive radiotherapy, automation, and AI integration.
• ElektacoreTechnology or Integration · 1 June 2021Supplier of the MR-Linac Unity system (1.5T MRI combined with linear accelerator). Radiotherapiegroep started MR-Linac treatments in June 2021. The organization participates in the MR-Linac Consortium for national and international knowledge sharing.
• RijnstatecoreStrategic or Co-development Partner · 1 January 2015Rijnstate is the main referring hospital in the ARTZ oncology network (with Ziekenhuis Gelderse Vallei and Slingeland Ziekenhuis). Radiotherapiegroep and Rijnstate jointly developed an innovative prostate cancer dashboard for shared decision-making between surgery and radiotherapy. Rijnstate performs prostate cancer surgeries while Radiotherapiegroep provides radiotherapy.
• Deventer ZiekenhuiscoreStrategic or Co-development Partner · 1 January 2015Part of the Veluwe IJssel Oncology Network along with Gelre ziekenhuizen, Isala, and Radiotherapiegroep. Deventer Ziekenhuis is a key referring hospital. Collaboration includes shared infrastructure (warmtepomp installed in collaboration with Deventer Ziekenhuis).
• Gelre ziekenhuizencoreStrategic or Co-development Partner · 1 January 2015Gelre ziekenhuizen in Apeldoorn hosts Radiotherapiegroep's fourth treatment location at the rear of the hospital. Part of the Veluwe IJssel Oncology Network. The co-location enables integrated oncology care for patients in the Apeldoorn region.
• Ziekenhuis Gelderse ValleicoreStrategic or Co-development Partner · 1 January 2015Host hospital for Radiotherapiegroep's Ede location within the Oncologisch Centrum (wing D). Part of the ARTZ oncology network. Parking facilities shared with the hospital.
• Slingeland ZiekenhuiscoreChannel Partner/ Reseller/ Distributor · 1 January 2015Partner in the ARTZ oncology network. Referrer of radiotherapy patients to Radiotherapiegroep.
• Integraal Kankercentrum Nederland (IKNL)coreStrategic or Co-development Partner · 1 January 2015Collaboration focuses on consultation, cancer registration, data management, and scientific research. Radiotherapiegroep participates in national cancer registry and shares data for improvement of Dutch oncology care.
• Overleg Zelfstandig Radiotherapeutische Centra (OZRC)coreStrategic or Co-development Partner · 1 January 2015Radiotherapiegroep is a member of OZRC, which brings together the five independent radiotherapy institutes in the Netherlands (Radiotherapiegroep, Maastro, Instituut Verbeeten, ZRTI, RIF) for knowledge exchange and collaboration on quality, safety, innovation, and organizational development.
• Universitair Medisch Centrum Groningen (UMCG)minorStrategic or Co-development Partner · 1 January 2015Collaboration for proton therapy referrals and scientific research. UMCG is one of three Dutch proton therapy centers (alongside Maastro and HollandPTC) to which Radiotherapiegroep refers appropriate patients.
• MaastrocoreStrategic or Co-development Partner · 1 January 2015Partner for proton therapy referrals (Maastro in Maastricht) and co-lead of the OPERAI AI project. Maastro is one of three Dutch proton therapy centers.
• Holland Protonen Therapie Centrum (HollandPTC)minorStrategic or Co-development Partner · 1 January 2015One of three Dutch proton therapy centers (alongside UMCG and Maastro) to which Radiotherapiegroep refers appropriate patients for proton therapy evaluation.
• RadboudUMCminorStrategic or Co-development Partner · 1 January 2015Collaboration within the Onco Oost network (9 hospitals) for knowledge sharing, research, and care improvement. RadboudUMC is also co-initiator of the STARTREC-3 rectal cancer study alongside Antoni van Leeuwenhoek.
• Antoni van LeeuwenhoekminorStrategic or Co-development Partner · 1 January 2015Co-initiator of the STARTREC-3 study (rectal cancer organ preservation). Radiotherapiegroep treats the first patient in this national study investigating radiotherapy as an alternative to surgery for limited rectal tumors.
• Erasmus MCminorStrategic or Co-development Partner · 1 January 2015Collaboration on bladder brachytherapy research. Theoretical education for the in-service training of radiotherapy technologists takes place at Erasmus MC Academie in Rotterdam.

Scale indicators10 records

Recent moves9 records

Expansion highlights7 records

Broad incumbents

• Erasmus MC: Rotterdam-based academic medical center with a substantial radiotherapy department. Provides theoretical education for Radiotherapiegroep's CZO-accredited in-service training and collaborates on bladder brachytherapy research. Competes for complex oncology cases and research grants within the broader academic setting.
• RadboudUMC: Nijmegen-based academic medical center with a radiotherapy department, member of the Onco Oost network with Radiotherapiegroep, and co-initiator of the STARTREC-3 study with Antoni van Leeuwenhoek. Partial overlap on radiotherapy within a comprehensive hospital setting.
• NKI / Antoni van Leeuwenhoek: Comprehensive cancer center in Amsterdam with a large in-house radiotherapy department. Co-initiator with Radiotherapiegroep of the STARTREC-3 rectal cancer study. Overlaps in advanced radiotherapy but within a much broader oncology portfolio including surgery, chemotherapy, and research.
• UMCG (Universitair Medisch Centrum Groningen): Academic medical center operating one of three Dutch proton therapy centers to which Radiotherapiegroep refers appropriate patients. Competes for complex radiotherapy cases and clinical research leadership, but within a much broader hospital portfolio spanning all medical specialties.

Direct peers

• RIF (Radiotherapeutisch Instituut Friesland): Friesland-based independent radiotherapy institute and OZRC member serving the Northern Netherlands. Direct structural peer within the five-center OZRC consortium, with similar physician-led outpatient specialist services, modalities, and reimbursement model.
• ZRTI (Zuidwest Radiotherapeutisch Instituut): Vlissingen-based independent radiotherapy institute and OZRC member. Provides the same core radiotherapy services under Dutch basic health insurance reimbursement. Although smaller, it is structurally comparable and competes in the same Dutch independent-institute segment.
• Instituut Verbeeten: Tilburg-based independent radiotherapy institute and OZRC member. Directly comparable as a Dutch standalone radiotherapy center with similar modality mix and reimbursement structure. Serves the Brabant region and competes with Radiotherapiegroep for clinical research partnerships and talent.
• Maastro: Independent radiotherapy institute in Maastricht, the closest direct peer in the Netherlands. Co-member of OZRC (the five-center independent radiotherapy association) and partner in the OPERAI AI project. Operates proton therapy in addition to photon radiotherapy and serves as a national referral center for complex cases.

Emerging players

• Holland Protonen Therapie Centrum (HollandPTC): Delft-based proton therapy center and one of three Dutch proton facilities to which Radiotherapiegroep refers patients. Partial overlap: complementary modality for complex cases, but distinct service offering. Acts as upstream referral destination rather than direct competitor for standard radiotherapy.
• GenesisCare: International operator of outpatient radiotherapy and oncology centers, with presence across Australia, the UK, Spain, and the US. Operates a similar specialist outpatient radiotherapy model with advanced technology (including MR-Linac). Provides a benchmark for scale and clinical operating model in markets outside the Netherlands.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@RadiotherapiegroepBestralingen
• LinkedInlinkedin.com/company/radiotherapiegroep
• Instagraminstagram.com/radiotherapiegroep
• Xx.com/radiotherapiegr
• Facebookfacebook.com/Radiotherapiegroep

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Radiotherapiegroep